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1. Introduction
The medicine went over extremely increased developmental process in the last century. The 
early decades of twentieth century can be characterized by the descriptive medicine, when 
the different clinical entities were separated from each other on the basis of symptomatology 
of different diseases, and the role of classical physical examinations was emphasized. These 
years, we practically can't speak on the curative medical therapy (the surgery was an excep-
tion in this term).
From the mid of last century, different methods such as X-ray examinations, ultrasonography, 
and other iconographic methods (including a computer tomography, MRI examination meth-
ods, and radioisotope examinations) and different laboratory examinations (including the 
general approaching parameters, later the specific parameters to infection diseases, immuno-
logical disorders, and radioimmunoassays) entered into the different medical activities of the 
physicians. These above-mentioned changes in the medical practice resulted in an extremely 
strong development in making a correct diagnosis of the patients.
In the 1970s appeared the “problem-orientated medicine” both in the teaching and in the 
clinical practice. The aims of this period can be characterized by the logical planning and car-
rying out of examinations of patients with different disorders aimed at the correct diagnosis 
for patients. The medical therapy was not well emphasized as the diagnostics (of course, we 
have relatively little knowledge on the therapeutic possibilities).
The pharmacological research started very actively from the second part of the last cen-
tury. Some of the physicians recognized the facts that the results obtained in animal 
observations can't be applied directly in the human therapy (without some human obser-
vations). The human clinical pharmacology (as a very important branch of practical medi-
cal research) appeared from 1960s. The established clinical pharmacology introduced the 
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“evidence-based medicine” from 1980s. This period covered the correct diagnosis and sci-
entifically based (proved) therapy in terms of medicine. In the early years of this period, 
the drug actions were observed (later tested) on healthy human beings and in patients 
with different diagnosis. Following the first years appeared the randomized, prospective, 
multicentric, and multiclinical studies, and thereafter these studies were carried out in 
huge number of patients suffering from the same disorders.
The international organization of human drug research has been absolutely required the 
involvement of different nations from the different continents in the same studies (multina-
tional) studies. One of the many factors the selections of patients including the same study 
other problems (age, body weight, correct diagnosis, the same stadiums of the disease, cor-
rect laboratory parameters, genders, nutritional habits, used drugs, etc.). The selections of the 
patients into the different drug therapies had been carried out randomly. Physicians (who 
actively participated in carrying out these observations) were not informed on therapeutically 
applied drugs (similarly to the patients), because these studies were done in accordance to 
previously permitted protocol(s).
These observations were done absolutely in accordance to earlier and the strictly prepared 
protocols (time of drug administration, collection of biological samples (blood and urine), 
relevant examinations, food and fluid consumption, etc.), and the protocols were previously 
permitted by the national authorities (respecting the ethical and medical aspects, cost and 
benefit, dangers of treated patients, etc.).
The critical evaluation of efficiencies of different drugs (or drug combinations) included the very 
complicated computer participation in the pharmacological research. Meanwhile, the detailed 
therapeutic effects resulted in the “meta-analysis” of drug (or drug-combination) actions.
The results of these examinations led us to plan a “generally accepted therapeutically used 
form” of drug therapy in the everyday medical treatment (guidelines).
Medically, we have to understand that these studies depended on the results obtained in huge 
number of human observations; however, an actually present patient was only one from the 
patients participated in whole ones of the big studies. Surprisingly, the results obtained in 
one patient differed from those obtained in big randomized studies. Of course, the physicians 
recalled the insufficient complaints of patients or some other causes. Later on, many other 
possibilities existed to explain the insufficient medical therapies, and their became to be clear 
by the new results of molecular biology, genetics, immunology, immunohistochemistry, and 
of new development of medical science (molecular pharmacology, biochemical pharmacology 
pharmacogenetics, etc.).
In this century, the development of medical sciences has been in an extremely high speed in 
different fields (including the basic research and clinical research), which produced an abnor-
mally increased quantity and quality of our knowledge.
We have to realize that oncology is one of these fields indicating rapid changes from day to 
day. Consequently, the diagnostic and therapeutic possibilities in our hand are changing day 
to day. This is an absolutely new challenge to physicians and this offers new possibilities for 
the patients.
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Gastric cancer remains an important issue in the world of oncology. In 2013, it was ranked fifth 
by the global incidence and second by mortality. It’s true that the death rates have decreased 
significantly in the USA and Europe over the near one hundred year period; meanwhile, gastric 
cancer is characterized by poor prognosis and high mortality, except in early diagnosed cases. 
The well-known histology of gastric cancer clearly indicates the correct diagnosis of disease, 
and the National Comprehensive Cancer Network (NCCN) indicates therapeutic guidelines to 
treat the patients with gastric cancer (recently Gastric Cancer, Version I.2017 – March 21, 2017. 
www.NCCN.org).
The oncological research in gastric cancer covers the classical clinical examinations, genet-
ics, iconography, molecular biology, biochemical pharmacology, modern immunohistochem-
istry, clinical pharmacology, immunology, medicine, gastroenterology, surgery, oncology, 
nutrition, chemical toxicology, modern bacteriology, and virology.
The book gives an excellent cross section of the different oncological studies done in the 
last years and offers absolutely new knowledge both for basic and clinical researchers 
(role of Epstein-Barr virus in tumor genesis, gastric carcinoma stem cells, molecular het-
erogeneity, prognostic factors, treatment strategies, the actualities in the targeting ther-
apy, responsibility of pathologists in the diagnosis and therapeutic decisions) and these 
together indicate clearly the change in our therapeutic strategies in the field of malignant 
disease.
The present book contains 11 excellent book chapters, which indicate the most recently 
obtained results in the fields of researches on gastric cancer. The participants of this book are 
basic and clinical researchers from Chile, Spain, France, Slovenia, Romania, Japan, Slovakia, 
Latvia, Germany, and Brazil.
The results of these above-mentioned observations are going on the border existing between 
the results of classical multiclinical, randomized, prospective, and multinational studies 
(including the presently applied and internationally accepted protocols) vs. the scientifically 
based (however individual) molecular targeting organ therapies (respectively the updated 
new results of molecular biological, immunological, immunohistochemical observations, 
etc.). These scientific and medical challenges a priori suggest the fruitful cooperation between 
the different research and medical treatment centers all over the world and offer new era of 
therapies of malignant disorders (including gastric cancer).
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